The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | Cardiovascular risk factors and pulmonary hypertension in patients with MPNs
Gaby Hobbs, MD, Massachusetts General Hospital, Boston, MA, discusses the importance of managing cardiovascular risk factors in patients with myeloproliferative neoplasms (MPNs), particularly in polycythemia vera (PV) and essential thrombocythemia (ET), to reduce the risk of thrombotic events. Pulmonary hypertension can also occur in patients with MPNs, implying that this cardiovascular event may be a prognostic factor for clinicians to use when diagnosing and managing patients. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Abbvie, BMS, GSK, Novartis, Pfizer, Pharmaessentia, Incyte.
